CDKN2A and neoplasm: Acriflavine, a HIF-1 inhibitor prevents dimerization of the HIF complex and reduces LSC formation, maintenance, survival and stemness through three mechanisms [17,173,174]: depleting c-Myc at mRNA and protein levels, promoting expression of tumour suppressors (e.g., p57, p19Arf and p16Ink4a) and inhibiting genes that favour LSC stemness (e.g., NANOG, Oct4, Sox9).